{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:27:08Z","timestamp":1772638028925,"version":"3.50.1"},"reference-count":102,"publisher":"Edizioni Minerva Medica","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ital J Dermatol Venereol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.23736\/s2784-8671.25.08372-0","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:53:27Z","timestamp":1762160007000},"source":"Crossref","is-referenced-by-count":0,"title":["Label and off-label treatment of dermatological diseases with JAK and TYK inhibitors"],"prefix":"10.23736","volume":"161","author":[{"given":"Carlo","family":"PIPIT\u00d2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"MARINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"PRIGNANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17149","reference":[{"key":"10.23736\/S2784-8671.25.08372-0_ref001","unstructured":"O'Shea JJ, Gadina M, Siegel RM. Cytokines and cytokine receptors. In: Paul WE, editor. Fundamental Immunology. 7th ed. Philadelphia: Lippincott Williams &amp; Wilkins; 2012. p. 865-908."},{"key":"10.23736\/S2784-8671.25.08372-0_ref002","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"10.23736\/S2784-8671.25.08372-0_ref003","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"10.23736\/S2784-8671.25.08372-0_ref004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103223441207"},{"key":"10.23736\/S2784-8671.25.08372-0_ref005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"10.23736\/S2784-8671.25.08372-0_ref006","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202576"},{"key":"10.23736\/S2784-8671.25.08372-0_ref007","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key276"},{"key":"10.23736\/S2784-8671.25.08372-0_ref008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"10.23736\/S2784-8671.25.08372-0_ref009","first-page":"379","article-title":"Incidence of malignancy in patients with psoriatic arthritis treated with tofacitinib: data from a global clinical program","volume":"43","author":"Mease P","year":"2020","journal-title":"Drug Saf"},{"key":"10.23736\/S2784-8671.25.08372-0_ref010","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"10.23736\/S2784-8671.25.08372-0_ref011","unstructured":"O'Shea JJ, Gadina M, Siegel RM. Cytokines and cytokine receptors. In: Firestein GS, Budd RC, Gabriel SE, editors. Firestein &amp; Kelley's Textbook of Rheumatology. 11th edition. Elsevier; 2020."},{"key":"10.23736\/S2784-8671.25.08372-0_ref012","first-page":"vi3","article-title":"Mechanisms of action of JAK inhibitors in rheumatoid arthritis: scientific rationale and clinical implications","volume":"58","author":"Choy EH","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.23736\/S2784-8671.25.08372-0_ref013","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902819"},{"key":"10.23736\/S2784-8671.25.08372-0_ref014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"10.23736\/S2784-8671.25.08372-0_ref015","first-page":"660","article-title":"Patient-reported outcomes from BRAVE-AA1 and BRAVE-AA2: two Phase 3 trials of Baricitinib in alopecia areata","volume":"88","author":"King B","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref016","first-page":"1771","article-title":"A safety overview of Baricitinib in clinical trials across multiple diseases","volume":"58","author":"Mease PJ","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.23736\/S2784-8671.25.08372-0_ref017","first-page":"1211","article-title":"Baricitinib in moderate-to-severe atopic dermatitis: results from two randomized monotherapy phase III trials (BREEZE-AD1 and BREEZE-AD2)","volume":"82","author":"Simpson EL","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref018","first-page":"242","article-title":"Efficacy and safety of Baricitinib combined with topical corticosteroids for moderate-to-severe atopic dermatitis: results from a randomized double-blind, placebo-controlled, phase III trial (BREEZE-AD7)","volume":"184","author":"Reich K","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref019","first-page":"843","article-title":"Baricitinib in the treatment of atopic dermatitis: efficacy and safety from the combined analysis of the BREEZE-AD phase 3 trials","volume":"11","author":"Papp KA","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.23736\/S2784-8671.25.08372-0_ref020","doi-asserted-by":"publisher","DOI":"10.1002\/art.38745"},{"key":"10.23736\/S2784-8671.25.08372-0_ref021","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98814"},{"key":"10.23736\/S2784-8671.25.08372-0_ref022","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17344"},{"key":"10.23736\/S2784-8671.25.08372-0_ref023","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140392"},{"key":"10.23736\/S2784-8671.25.08372-0_ref024","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14039"},{"key":"10.23736\/S2784-8671.25.08372-0_ref025","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14074"},{"key":"10.23736\/S2784-8671.25.08372-0_ref026","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9619586"},{"key":"10.23736\/S2784-8671.25.08372-0_ref027","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15642"},{"key":"10.23736\/S2784-8671.25.08372-0_ref028","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.025"},{"key":"10.23736\/S2784-8671.25.08372-0_ref029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.09.017"},{"key":"10.23736\/S2784-8671.25.08372-0_ref030","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.02.027"},{"key":"10.23736\/S2784-8671.25.08372-0_ref031","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_1511_2024"},{"key":"10.23736\/S2784-8671.25.08372-0_ref032","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"10.23736\/S2784-8671.25.08372-0_ref033","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100099"},{"key":"10.23736\/S2784-8671.25.08372-0_ref034","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.5737"},{"key":"10.23736\/S2784-8671.25.08372-0_ref035","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1008392"},{"key":"10.23736\/S2784-8671.25.08372-0_ref036","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13786"},{"key":"10.23736\/S2784-8671.25.08372-0_ref037","first-page":"629","article-title":"In vitro and in vivo characterization of Upadacitinib (ABT-494), a selective JAK1 inhibitor","volume":"365","author":"Parmentier JM","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.23736\/S2784-8671.25.08372-0_ref038","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"10.23736\/S2784-8671.25.08372-0_ref039","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0391"},{"key":"10.23736\/S2784-8671.25.08372-0_ref040","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"10.23736\/S2784-8671.25.08372-0_ref041","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01157-5"},{"key":"10.23736\/S2784-8671.25.08372-0_ref042","first-page":"1389","article-title":"Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)","volume":"14","author":"Guttman-Yassky E","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.23736\/S2784-8671.25.08372-0_ref043","first-page":"863","article-title":"Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)","volume":"85","author":"Simpson EL","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref044","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.001"},{"key":"10.23736\/S2784-8671.25.08372-0_ref045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.056"},{"key":"10.23736\/S2784-8671.25.08372-0_ref046","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.01.014"},{"key":"10.23736\/S2784-8671.25.08372-0_ref047","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17339"},{"key":"10.23736\/S2784-8671.25.08372-0_ref048","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19462"},{"key":"10.23736\/S2784-8671.25.08372-0_ref049","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.046"},{"key":"10.23736\/S2784-8671.25.08372-0_ref050","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.08.002"},{"key":"10.23736\/S2784-8671.25.08372-0_ref051","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad498.066"},{"key":"10.23736\/S2784-8671.25.08372-0_ref052","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1016"},{"key":"10.23736\/S2784-8671.25.08372-0_ref053","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.01.033"},{"key":"10.23736\/S2784-8671.25.08372-0_ref054","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1476793"},{"key":"10.23736\/S2784-8671.25.08372-0_ref055","first-page":"280","article-title":"Response of palmoplantar pustulosis to upadacitinib","volume":"21","author":"Mohr J","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.23736\/S2784-8671.25.08372-0_ref056","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.05.009"},{"key":"10.23736\/S2784-8671.25.08372-0_ref057","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7645"},{"key":"10.23736\/S2784-8671.25.08372-0_ref058","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"10.23736\/S2784-8671.25.08372-0_ref059","first-page":"AB47","article-title":"Abrocitinib Significantly Reduces Itch Frequency and Severity: A Post Hoc Analysis of Phase 3 Studies in Atopic Dermatitis","volume":"90","author":"Guttman-Yassky E","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref060","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.025"},{"key":"10.23736\/S2784-8671.25.08372-0_ref061","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.078"},{"key":"10.23736\/S2784-8671.25.08372-0_ref062","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.39822"},{"key":"10.23736\/S2784-8671.25.08372-0_ref063","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.1464"},{"key":"10.23736\/S2784-8671.25.08372-0_ref064","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad129"},{"key":"10.23736\/S2784-8671.25.08372-0_ref065","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1416004"},{"key":"10.23736\/S2784-8671.25.08372-0_ref066","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19992"},{"key":"10.23736\/S2784-8671.25.08372-0_ref067","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"10.23736\/S2784-8671.25.08372-0_ref068","first-page":"e91","article-title":"Efficacy and safety of the oral Janus kinase 3\/TEC family kinase inhibitor Ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata","volume":"190","author":"King B","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref069","first-page":"109","article-title":"Integrated safety analysis of Ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King B","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref070","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.01.090"},{"key":"10.23736\/S2784-8671.25.08372-0_ref071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.005"},{"key":"10.23736\/S2784-8671.25.08372-0_ref072","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118828"},{"key":"10.23736\/S2784-8671.25.08372-0_ref073","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.961"},{"key":"10.23736\/S2784-8671.25.08372-0_ref074","first-page":"e1","article-title":"Safety and efficacy of Ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years","volume":"189","author":"Lebwohl MG","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref075","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085"},{"key":"10.23736\/S2784-8671.25.08372-0_ref076","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18571"},{"key":"10.23736\/S2784-8671.25.08372-0_ref077","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01219-8"},{"key":"10.23736\/S2784-8671.25.08372-0_ref078","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14192"},{"key":"10.23736\/S2784-8671.25.08372-0_ref079","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.016"},{"key":"10.23736\/S2784-8671.25.08372-0_ref080","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.11.027"},{"key":"10.23736\/S2784-8671.25.08372-0_ref081","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.12.018"},{"key":"10.23736\/S2784-8671.25.08372-0_ref082","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.015"},{"key":"10.23736\/S2784-8671.25.08372-0_ref083","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.11.036"},{"key":"10.23736\/S2784-8671.25.08372-0_ref084","first-page":"52","article-title":"Delgocitinib cream in adults with moderate to severe chronic hand eczema: results from the phase III DELTA 1 and DELTA 2 trials","volume":"189","author":"Bissonnette R","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref085","first-page":"189","article-title":"Efficacy and safety of Delgocitinib cream for the treatment of chronic hand eczema: results from two phase III randomized controlled trials (DELTA 1 and DELTA 2)","volume":"190","author":"Worm M","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref086","first-page":"275","article-title":"Long-term safety and efficacy of Delgocitinib ointment for chronic hand eczema: a phase 3, open-label extension study","volume":"50","author":"Yano T","year":"2023","journal-title":"J Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref087","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.014"},{"key":"10.23736\/S2784-8671.25.08372-0_ref088","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2023.04.003"},{"key":"10.23736\/S2784-8671.25.08372-0_ref089","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"10.23736\/S2784-8671.25.08372-0_ref090","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19925"},{"key":"10.23736\/S2784-8671.25.08372-0_ref091","first-page":"675","article-title":"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in plaque psoriasis: 3-year Psoriasis Area and Severity Index (PASI) outcomes in the long-term extension of the phase 3 POETYK PSO-1 and PSO-2 trials","volume":"92","author":"Armstrong AW","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref092","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391"},{"key":"10.23736\/S2784-8671.25.08372-0_ref093","doi-asserted-by":"crossref","unstructured":"Demirci SE, Tursen B. Safety, Toxicity Profile and Side Effects. In: T\u00fcrsen \u00dc, Karada\u011f AS, editors. Jak-Inhibitors in Dermatology. Springer; 2025. p. 131-139.","DOI":"10.1007\/978-3-031-84274-0_16"},{"key":"10.23736\/S2784-8671.25.08372-0_ref094","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01203-2"},{"key":"10.23736\/S2784-8671.25.08372-0_ref095","unstructured":"Pfizer. ORAL Surveillance Study | XELJANZ\u00ae (tofacitinib) | Safety Info; 2025 [Internet]. Available from: https:\/\/xeljanz.pfizerpro.com\/uc\/efficacy-safety\/safety-oral-surveillance-ra [cited 2025 Oct 8]."},{"key":"10.23736\/S2784-8671.25.08372-0_ref096","unstructured":"Therapeutic Goods Administration (TGA). Important safety information for Janus kinase (JAK) inhibitors; 2023 [Internet]. Available from: https:\/\/www.tga.gov.au\/news\/safety-updates\/important-safety-information-janus-kinase-jak-inhibitors [cited 2025 Oct 8]."},{"key":"10.23736\/S2784-8671.25.08372-0_ref097","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01243-8"},{"key":"10.23736\/S2784-8671.25.08372-0_ref098","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00892-5"},{"key":"10.23736\/S2784-8671.25.08372-0_ref099","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2020.12.003"},{"key":"10.23736\/S2784-8671.25.08372-0_ref100","first-page":"1103","article-title":"Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis","volume":"60","author":"Simpson EL","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.23736\/S2784-8671.25.08372-0_ref101","first-page":"316","article-title":"The ORAL Surveillance trial: safety of tofacitinib versus TNF inhibitors in rheumatoid arthritis","volume":"386","author":"Winthrop KL","year":"2022","journal-title":"N Engl J Med"},{"key":"10.23736\/S2784-8671.25.08372-0_ref102","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00767-7"}],"container-title":["Italian Journal of Dermatology and Venereology"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R23Y2026N01A0032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:28:00Z","timestamp":1772616480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R23Y2026N01A0032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":102,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.23736\/s2784-8671.25.08372-0","relation":{},"ISSN":["2784-8671","2784-8450"],"issn-type":[{"value":"2784-8671","type":"print"},{"value":"2784-8450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}